Fermenta Biotech Ltd
Fermenta Biotech Q4 FY25: Revenue ₹143.7 Cr, PAT ₹33.3 Cr
Q4 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹140Cr
- +43.7% YoY
- Net profit
- ₹33Cr
- Q4 FY24: −₹7 Cr
- Margin
- 26.42%
- +20.9 pp YoY
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Fermenta Biotech Ltd's Q4 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q4 FY25 Revenue: ₹143.7 crore - Up 40% year-on-year (YoY) - Down 9% quarter-on-quarter (QoQ) - FY25 Revenue: ₹481.3 crore - Up 39% YoY - Human nutrition volume grew by 48% over FY24 - Animal nutrition volume grew by 24% over FY24 - Q4 FY25 EBITDA: ₹40.8 crore (up 280% YoY, down 26% QoQ) - Q4 FY25 Revenue: ₹143.7 crore (up 40% YoY, down 9% QoQ) - Q4 FY25 Profit After Tax (PAT): ₹33.3 crore (up ₹40.5 crore YoY, down 12% QoQ) - Margins: The presentation reports an EBITDA margin jump to 26% for FY25 (page 9), reflecting strong cost control and improved realizations.
From Fermenta Biotech Ltd's Q4 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY25 Revenue: ₹143.7 crore
- Up 40% year-on-year (YoY)
- Down 9% quarter-on-quarter (QoQ)
- FY25 Revenue: ₹481.3 crore
- Up 39% YoY
2 more points from Fermenta Biotech Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY25 capex was ₹22 crore, slightly increased from ₹19 crore in FY24 (Page 11).
- Validation batches completed for spray dried (SD) variant of Vitamin D3 100,000 IU/g powder for human nutrition; qualification ongoing with global customers and regulators (Page 5).
- Commercial scale production achieved for plant-based Vitamin D3 active ingredient using proprietary technology; validation batches for plant-based D3 oil and spray dried powder variants completed; qualification process ongoing with global customers and regulatory authorities (Page 5).
- Capex expenditures appear focused on product development, scaling up production capabilities, and validating new variants rather than greenfield projects (inferred from context, Page 11 and 5).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Fermenta Biotech Ltd said on order book & pipeline — free account, 30 seconds.
Fermenta Biotech Ltd — Quarterly revenue & net profit
Fermenta Biotech Ltd Q4 FY25 results — key figures
| ₹ Cr | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 140 | 97 | +43.7% | 156 | -10.6% |
| Operating profit (EBITDA) | 37 | 5 | +586.8% | 53 | -30.6% |
| Operating margin | 26.42% | 5.53% | +20.9 pp | 34.04% | -7.6 pp |
| Profit before tax | 32 | 1 | +3415.4% | 45 | -29.4% |
| Net profit (PAT) | 33 | -7 | — | 38 | -12.1% |
| EPS (₹) | 11.68 | -2.36 | — | 12.54 | -6.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹133 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fermenta Biotech's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharmaceuticals (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Fermenta Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Fermenta Biotech Ltd Q4 FY25 results?
Q4 FY25 Revenue: ₹143.7 crore - Up 40% year-on-year (YoY) - Down 9% quarter-on-quarter (QoQ) - FY25 Revenue: ₹481.3 crore - Up 39% YoY - Human nutrition volume grew by 48% over FY24 - Animal nutrition volume grew by 24% over FY24 - Q4 FY25 EBITDA: ₹40.8 crore (up 280% YoY, down 26% QoQ) - Q4 FY25 Revenue: ₹143.7 crore (up 40% YoY, down 9% QoQ) - Q4 FY25 Profit After Tax (PAT): ₹33.3 crore (up ₹40.5 crore YoY, down 12% QoQ) - Margins: The presentation reports an EBITDA margin jump to 26% for FY25 (page 9), reflecting strong cost control and improved realizations.
What is Fermenta Biotech Ltd share price analysis?
Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fermenta Biotech Ltd planning capital expenditure?
FY25 capex was ₹22 crore, slightly increased from ₹19 crore in FY24 (Page 11). - Validation batches completed for spray dried (SD) variant of Vitamin D3 100,000 IU/g powder for human nutrition; qualification ongoing with global customers and regulators (Page 5). - Commercial scale production achieved for plant-based Vitamin D3 active ingredient using proprietary technology; validation batches for plant-based D3 oil and spray dried powder variants completed; qualification process ongoing with global customers and regulatory authorities (Page 5).
Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.